Topotecan

Adult: 1.5 mg/m²/day by IV infusion over 30 min on days 1-5 of a 21-day course. Min: 4 courses to be given (provided blood counts and haemoglobin have adequately recovered). In the event of severe neutropenia or platelet count falls below 25,000 cells/mm³, reduce dose to 1.25 mg/m². Alternatively, in the event of severe neutropenia, granulocyte colony-stimulating factor (G-CSF) to be given following the subsequent course (before resorting to dose reduction) starting from day 6 of the course (24 hr after topotecan treatment completion).

Adult: As combination therapy with cisplatin: 0.75 mg/m², by IV infusion over 30 min on days 1, 2 and 3 of a 21-day course; cisplatin 50 mg/m² as IV infusion after topotecan on day 1. Dosage adjustments for subsequent courses are specific for each drug. If severe febrile neutropenia or if the platelet count drops below 10,000 cells/mm³, topotecan dose to be reduced to 0.6 mg/m². Alternatively, in severe febrile neutropenia, granulocyte colony-stimulating factor (G-CSF) to be given from day 4 of the subsequent course (before resorting to dose reduction), 24 hr after topotecan treatment completion; if febrile neutropenia recurs despite G-CSF , topotecan dosage to be further reduced to 0.45 mg/m² for subsequent courses.

Adult: 2.3 mg/m² once daily for 5 consecutive days, repeat every 21 days. If neutropenia, or if platelet count drops below 25,000 cells/mm³ or for patient w/ severe diarrhoea, reduce dose to 400 mcg/m² (to 1.9 mg/m² daily, and subsequently to 1.5 mg/m² daily).